Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


3M panel cancelled

This article was originally published in The Gray Sheet

Executive Summary

Lung sealant's previously planned May 12 review by FDA's General & Plastic Surgery Devices Panel is cancelled "by mutual agreement between FDA and the sponsor," according to the agency. 3M characterizes the move as a business decision; the in situ polymerizable sealant remains likely to require panel review at a later date. Results from a five-center, prospective, randomized trial suggesting reduced hospital stays with the sealant are scheduled for May publication in the Annals of Thoracic Surgery (1"The Gray Sheet" April 26, 2004, p. 14)...

You may also be interested in...

FDA Panel To Weigh Whether 3M Sealant Effectively Closes Pulmonary Leaks

3M's lung sealant may shorten hospital stays for lung surgery patients, according to a study led by Mark Allen, MD, Mayo Clinic

India Lifts Export Restrictions

India has removed export restrictions on APIs and formulations imposed by the country in March. However, certain measures have been kept in place to ensure that domestic requirements are met for in-demand products such as hydroxychloroquine and paracetamol.

Takeda’s Alunbrig To Battle Entrenched EU Competitors In First-Line ALK-Positive NSCLC

EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts